News
TNXP
11.67
-5.05%
-0.62
Tonix Advances TNX-102 SL Into Phase 2 Depression Trial, Drawing Investor Focus
TipRanks · 1h ago
Tonix shares TNX-4800 Lyme disease prevention presentation
PUBT · 1d ago
Tonix Pharmaceuticals publishes investor deck highlighting TONMYA fibromyalgia launch, pipeline updates
PUBT · 1d ago
Alliance Global Partners Sticks to Their Buy Rating for Tonix Pharma (TNXP)
TipRanks · 1d ago
Weekly Report: what happened at TNXP last week (0525-0529)?
Weekly Report · 1d ago
Tonix presents data from analysis of opioid use in adults with fibromyalgia
TipRanks · 4d ago
Tonix Pharma Presents Data From Real-World Claims Analysis Of Opioid Use In US Adults With Fibromyalgia At 2026 ASCP Annual Meeting
Benzinga · 4d ago
Tonix presents real-world claims analysis showing persistent opioid prescribing in US fibromyalgia patients
PUBT · 4d ago
Tonix Pharmaceuticals publishes TNX-1500 data in Journal of Clinical Immunology
TipRanks · 6d ago
Tonix Pharma Highlights Positive Phase 1 TNX-1500 Results
TipRanks · 6d ago
Tonix Pharmaceuticals posts investor deck spotlighting TONMYA fibromyalgia launch strategy
PUBT · 6d ago
Tonix Pharmaceuticals' TNX-1500 Shows Favorable Safety Profile In Phase 1 Study As Phase 2 Kidney Transplant Trial Set For 2nd Half 2026
Benzinga · 6d ago
Tonix reports Phase 1 data for TNX-1500 anti-CD40L antibody in healthy adults, supports monthly IV dosing
PUBT · 6d ago
Tonix Pharmaceuticals publishes investor deck highlighting TONMYA fibromyalgia launch strategy
PUBT · 6d ago
Analysts Offer Insights on Healthcare Companies: Daxor (DXR) and Tonix Pharma (TNXP)
TipRanks · 05/26 14:00
Tonix Pharmaceuticals presents data from analysis of adults with fibromyalgia
TipRanks · 05/26 11:57
Tonix Pharmaceuticals' ISPOR 2026 Data Show 93.2% Comorbidity Burden And $29,896 Annual Inpatient Costs Among Fibromyalgia Patients
Benzinga · 05/26 11:09
Tonix presents real-world U.S. claims analysis of 261,776 fibromyalgia patients at ISPOR 2026
PUBT · 05/26 11:03
Press Release: Tonix Pharmaceuticals Presented -2-
Dow Jones · 05/26 11:00
Press Release: Tonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at The Professional Society for Health Economics and Outcomes Research (ISPOR) 2026 Annual Meeting
Dow Jones · 05/26 11:00
More
Webull provides a variety of real-time TNXP stock news. You can receive the latest news about Tonix Pharmaceut through multiple platforms. This information may help you make smarter investment decisions.
About TNXP
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing and commercializing therapeutics to treat and vaccines to prevent, disease and alleviate suffering. Its development portfolio is focused on central nervous system (CNS) disorders. Its product candidates include TNX-102 SL, TNX-1300, TNX-2900, TNX-1900, TNX-1500, TNX-801, TNX-1800, TNX-4200, and TNX-1700. TNX-102 SL is for the management of fibromyalgia. Its CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has a therapy designation. Its immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. It markets Zembrace SymTouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg.